|Bid||4.46 x 2000|
|Ask||4.99 x 5000|
|Day's range||4.46 - 4.80|
|52-week range||3.75 - 19.30|
|PE ratio (TTM)||N/A|
|Earnings date||31 Jul 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.60|
NewLink Genetics Corporation (NLNK), reported that updated Phase 1 data evaluating indoximod plus front-line radiation and maintenance chemotherapy for the treatment of pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) were presented Sunday, July 1, at the International Symposium of Pediatric Neuro-Oncology (ISPNO) 2018 Annual Meeting in Denver. Data were presented on ten newly diagnosed DIPG patients, all of whom had initiated therapy at the time of this assessment. “These data continue to demonstrate the potential for indoximod plus radiochemotherapy as a combination treatment regimen which may improve disease related symptoms for these pediatric patients with an otherwise dire prognosis,” said Dr. Theodore S. Johnson, M.D., Ph.D., Associate Professor of Pediatrics at Augusta University, lead investigator for the trial.
NewLink Genetics Corporation today announced that data from two Phase 2 studies of indoximod, used in combination with other agents, were presented at the 2018 American Society of Clinical Oncology Annual Meeting.
The Ames, Iowa-based company said it had a loss of 49 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
NewLink Genetics Corporation today presented a poster entitled “Indoximod modulates AhR-driven transcription of genes that control immune function” in the Immunomodulatory Agents and Interventions session at the American Association for Cancer Research 2018 Annual Meeting in Chicago.
NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.
Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.
Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.
The Ames, Iowa-based company said it had a loss of 37 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation into potential breaches of fiduciary duty by the Company’s Board of Directors .
The Ames, Iowa-based company said it had a loss of 69 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for ...
NewLink Genetics Corporation , a late-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market conditions, up to $50,000,000 of shares of its common stock in an underwritten public offering.